Denis Vivien

Les travaux de Denis Vivien et de ses collaborateurs ont donné lieu à la publication de près de 112 articles originaux dans des revues scientifiques internationales et à des dépôts de brevets.

Sélection des principales publications

• Nicole O, Ali C, Docagne F, Plawinski L, Mackenzie ET, Vivien D, Buisson A. Neuroprotection mediated by glial cell line-derived neurotrophic factor (gdnf): involvement of a reduction of nmda-induced calcium influx by the mitogen-activated protein kinase pathway. J Neurosci 21: 3024- 33, 2001.
• Nicole O, Docagne F, Ali C, Carmeliet P, Mackenzie ET, Vivien D *, Buisson A*. *Authors With Equal Contribution. The proteolytic activity of tissue plasminogen activator enhances glutamatergic neurotransmission. Nat Med 7: 59-64, 2001.
• Vivien D, Fernandez-Monreal M, Nicole O, Buisson A. Tissue plasminogen activator and nmda receptor cleavage. Nat Med 9: 371-72, 2003. (Lettre).
• Maillet M, Robert S, Cacquevel M, Gastneau M, Vivien D, Bertoglio J, Zugaza J, Fishmeister R And Lezouach F. A new cross-talk between rap-1 and rac involving cyclic amp. Nat Cell Biol 5: 633-39, 2003.
• Fernandez-Monreal M, Lopez-Atalaya Jp, Benchenane K, Cacquevel M, Dulin F, Le Caer JP, Rossier J, Jarrige AC, Mackenzie ET, Colloc'h N, Ali C, Vivien D. Arginine 260 of the amino-terminal domain of nr1 subunit is critical for tissue-type plasminogen activator-mediated enhancement of nmda receptor signalling. J Biol Chem 279: 50850-856, 2004.
• Benchenane K, Berezowski V, Ali C, Lopez-Atalaya J, Fernandez Monreal M, Brillault J, Chuquet J, Bu G, Nouvelot A, Mackenzie ET, Cecchelli R, Touzani O, Vivien D. Tissue type plasminogen activator crosses the intact blood brain barrier by ldl-related receptor protein-mediated transcytosis. Circulation 111: 2241-49, 2005.
• Lesne S, Ali C, Gabriel C, Croci N, Mackenzie ET, Glabe CG, Plotkine M, Marchand- Verrecchia C, Vivien D, Buisson A. Nmda receptor activation inhibits alpha-secretase and promotes neuronal amyloid- beta production. J Neurosci 25: 9367-9377, 2005.
• Launay S, Maubert E, Lebeurrier N, Tennstaedt A, Campioni M, Docagne F, Gabriel C, Dauphinot L, Potier MC, Ehrmann M, Baldi A, Vivien D. HtrA1-dependent proteolysis of TGF-beta controls both neuronal maturation and developmental survival. Cell Death Differ 15: 1408-116, 2008.
• Roussel BD, Macrez R, Jullienne A, Agin V, Maubert E, Dauphinot L, Potier MC, Plawinski L, Castel H, Hommet Y, Munuera J, Montaner J, Yepes M, Ali C, Vivien D. Age and albumin D site- binding protein control tissue plasminogen activator levels: neurotoxic impact. Brain 132: 2219-30, 2009.
• Baron A, Montagne A, Casse F, Launay S, Maubert E, Ali C, Vivien D. NR2D containing NMDA receptors mediate tissue plasminogen activator-promoted neuronal excitotocicity. Cell death Differ; 17: 860-71, 2010.
• Gakuba C, Gauberti M, Mazighi M, Defer G, Hanouz JL, Vivien D. Preclinical Evidence Toward the Use of Ketamine for Recombinant Tissue-Type Plasminogen Activator-Mediated Thrombolysis Under Anesthesia or Sedation. Stroke 42: 2947-49, 2011.
• Macrez R, Obiang P, Gauberti M, Roussel B, Baron A, Parcq J, Cassé F, Hommet Y, Orset C, Agin V, Bezin L, Berrocoso TG, Petersen KU, Montaner J, Maubert E, Vivien D, Ali C. Antibodies preventing the interaction of tissue-type plasminogen activator with N-methyl-d-aspartate receptors reduce stroke damages and extend the therapeutic window of thrombolysis. Stroke 42: 2315-22, 2011.
• Correa F, Gauberti M, Parcq J, Macrez R, Hommet Y, Obiang P, Hernangómez M, Montagne A, Liot G, Guaza C, Maubert E, Ali C, Vivien D, Docagne F. Tissue plasminogen activator prevents white matter damage following stroke. J Exp Med 208: 1229-42, 2011.
• Parcq J, Bertrand T, Montagne A, Baron AF, Macrez R, Billard JM, Briens A, Hommet Y, Wu J, Yepes M, Lijnen HR, Dutar P, Anglés-Cano E, Vivien D. Unveiling an exceptional zymogen: the single-chain form of tPA is a selective activator of NMDA receptor-dependent signaling and neurotoxicity. Cell Death Differ 19(12): 1983-91, 2012.
• Obiang P, Macrez R, Jullienne A, Bertrand T, Lesept F, Ali C, Maubert E, Vivien D*, Agin V*. GluN2D subunit-containing NMDA receptors control tissue plasminogen activator-mediated spatial memory. J Neurosci 32(37): 12726-34, 2012.
• Montagne A, Gauberti M, Macrez R, Jullienne A, Briens A, Raynaud JS, Louin G, Buisson A, Haelewyn B, Docagne F, Defer G, Vivien D*, Maubert E*. Ultra-sensitive molecular MRI of cerebrovascular cell activation enables early detection of chronic central nervous system disorders. Neuroimage 63(2): 760-70, 2012.
• Cassé F, Bardou I, Danglot L, Briens A, Montagne A, Parcq J, Alahari A, Galli T, Vivien D*, Docagne F*. Glutamate controls tPA recycling by astrocytes, which in turn influences glutamatergic signals. J Neurosci 32: 5186-99, 2012.
• Gakuba C, Gauberti M, Vivien D. Endovascular treatment for acute ischemic stroke. N Engl J Med 20; 368(25): 2430-1, 2013.
• Gauberti M, Martinez de Lizarrondo S, Orset C, Vivien D. Lack of secondary microthrombosis after thrombin-induced stroke in mice and non-human primates. J Thromb. Haemost 12: 409-14, 2014.
• Le Behot A, Gauberti M, Martinez de Lizarrondo S, Montagne A, Lemarchand E, Repesse Y, Guillou S, Denis CV, Maubert E, Orset C, Vivien D. GpIbα-VWF blockade restores vessel patency by dissolving platelet aggregates formed under very high shear rate in mice. Blood 2014 Feb 19. [Epub ahead of print]

Brevets

• WO2011023250A1 - EP2473185 A1. Treatment of thrombotic diseases and stroke”, déposés et publiés le 03/03/201. Under licence for Inserm-Transfert and Paion GmbH.
• W02013/034710A1. Mutated tissue plasminogen activators and uses thereof. EP11306119.6, 09/2012, Under licence for Inserm-Transfort and Theraprot.